نتایج جستجو برای: flt3 tyrosine kinase

تعداد نتایج: 262799  

Journal: :Cancer research 2014
Hayley S Ma Bao Nguyen Amy S Duffield Li Li Allison Galanis Allen B Williams Patrick A Brown Mark J Levis Daniel J Leahy Donald Small

There have been a number of clinical trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors (TKI) in patients with acute myeloid leukemia (AML) harboring a constitutively activating mutation in FLT3. However, there has been limited efficacy, most often because of inadequate achievement of FLT3 inhibition through a variety of mechanisms. In a previous study, ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2003
Anne-Marie O'Farrell James M Foran Walter Fiedler Hubert Serve Ron L Paquette Maureen A Cooper Helene A Yuen Sharianne G Louie Heidi Kim Susan Nicholas Michael C Heinrich Wolfgang E Berdel Carlo Bello Mark Jacobs Paul Scigalla William C Manning Stephen Kelsey Julie M Cherrington

PURPOSE Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived growth factor receptor alpha/beta, vascular endothelial growth factor receptor 1/2, and KIT receptor tyr...

ژورنال: :مجله بین المللی علوم آزمایشگاهی 0
محمد مهدی کوشیار mohammad mehdi kooshyar محمدهادی صادقیان mohammad hadi sadeghian محمدرضا کرامتی mohammad reza keramati حسین رحیمی hossein rahimi سیده فاطمه شمس seyyede fatemeh shams سپیده شاکری sepideh shakeri حسین ایت اللهی

مقدمه: میلوم مالتیپل تکثیر بی رویه ی پلاسما سل ها از یک کلون بدخیم است. تومور ، محصولات ناشی از آن و پاسخ ایمنی میزبان منجر به آسیب ارگان ها می شود. بعضی فاکتورهای مرتبط با پاتوژنر بیماری شناخته شده اند. از آنجایی که موتاسیون های flt3 در لوسمی ها به عنوان یک فاکتور تعیین کننده شناخته می شود هدف این مطالعه بررسی رابطه ی بین موتاسیون های itd (internal tandem duplication) flt3 وflt3 tkd(tyrosine k...

Journal: :Molecular cancer research : MCR 2010
Rehan Ahmad Suiyang Liu Ellen Weisberg Erik Nelson Ilene Galinsky Colin Meyer Donald Kufe Surender Kharbanda Richard Stone

Mutations of the FLT3 receptor tyrosine kinase consisting of internal tandem duplications (ITD) have been detected in blasts from 20% to 30% of patients with acute myeloid leukemia (AML) and are associated with a poor prognosis. FLT3/ITD results in constitutive autophosphorylation of the receptor and factor-independent survival in leukemia cell lines. The C-28 methyl ester of the oleane triterp...

Journal: :Cancer research 2005
Christian H Brandts Bülent Sargin Miriam Rode Christoph Biermann Beate Lindtner Joachim Schwäble Horst Buerger Carsten Müller-Tidow Chunaram Choudhary Martin McMahon Wolfgang E Berdel Hubert Serve

Up to 30% of patients with acute myeloid leukemia (AML) harbor internal tandem duplications (ITD) within the FLT3 gene, encoding a receptor tyrosine kinase. These mutations induce constitutive tyrosine kinase activity in the absence of the natural Flt3 ligand and confer growth factor independence, increased proliferation, and survival to myeloid precursor cells. The signaling pathways and downs...

Journal: :Blood 2014
Allison Galanis Hayley Ma Trivikram Rajkhowa Abhijit Ramachandran Donald Small Jorge Cortes Mark Levis

Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease. As more potent FLT3 inhibitors are developed, a predictable development of resistance-conferring point mutations, co...

2004
Richard M. Stone Daniel J. DeAngelo Virginia Klimek Ilene Galinsky Eli Estey Stephen D. Nimer Wilson Grandin David Lebwohl Yanfeng Wang Pamela Cohen Edward A. Fox Donna Neuberg Jennifer Clark D. Gary Gilliland James D. Griffin

Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/ refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (...

Journal: :Blood 2004
Yiwen Li Hongli Li Mei-Nai Wang Dan Lu Rajiv Bassi Yan Wu Haifan Zhang Paul Balderes Dale L Ludwig Bronislaw Pytowski Paul Kussie Obdulio Piloto Donald Small Peter Bohlen Larry Witte Zhenping Zhu Daniel J Hicklin

FMS-like tyrosine kinase 3 (FLT3), a class III receptor tyrosine kinase, is expressed at high levels in the blasts of approximately 90% of patients with acute myelogenous leukemia (AML). Internal tandem duplications (ITDs) in the juxtamembrane domain and point mutations in the kinase domain of FLT3 are found in approximately 37% of AML patients and are associated with a poor prognosis. We repor...

2013
Sylvia-Annette Böhmer Irene Weibrecht Ola Söderberg Frank-D. Böhmer

Protein-tyrosine phosphatases (PTPs) are important regulators of signal transduction processes. Essential for the functional characterization of PTPs is the identification of their physiological substrates, and an important step towards this goal is the demonstration of a physical interaction. The association of PTPs with their cellular substrates is, however, often transient and difficult to d...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Daniel E Lopes de Menezes Jing Peng Evelyn N Garrett Sharianne G Louie Sang H Lee Marion Wiesmann Yan Tang Lee Shephard Cheryl Goldbeck Yoko Oei Helen Ye Sharon L Aukerman Carla Heise

PURPOSE Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for which activating mutations have been identified in a proportion of acute myelogenous leukemia (AML) patients and associated with poor clinical prognosis. Given the relevance of FLT3 mutations in AML, we investigated the activity of CHIR-258, an orally active, multitargeted small molecule, with potent activity...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید